Compare RCG & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RCG | OSRH |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 18.4M |
| IPO Year | N/A | N/A |
| Metric | RCG | OSRH |
|---|---|---|
| Price | $2.74 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.9K | ★ 3.0M |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.52 | $0.45 |
| 52 Week High | $1.90 | $11.84 |
| Indicator | RCG | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 60.80 | 42.33 |
| Support Level | $2.60 | $0.56 |
| Resistance Level | $2.75 | $0.67 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 70.82 | 9.63 |
RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.